Abstract
Parkinson's disease treatment can be divided into three categories: symptomatic, protective and restorative. This review focuses on the restorative and neuroprotective actions of a new class of potential therapeutic agents, neuroimmunophilin ligands. To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 82-86 |
| Number of pages | 5 |
| Journal | Current Opinion in Pharmacology |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 1 2002 |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery